6月20日,佰泽医疗暗盘开涨超30%,报5.5港元/股,总市值超72亿港元;不计手续费,中签一手赚768港元;公司每股定价4.22港元,每手600股,将于6月23日(周一)正式挂牌交易。
佰泽医疗集团有限公司成立于2017年,专注于提供肿瘤“防-筛-诊-治-康”全周期、全链条的医疗服务,并为旗下医院提供医疗资源、管理经验,对其进行精细化运营管理。自2023年3月起,经中国政府批准,太原和平医院由二级甲等综合医院升级为三级康复专科医院,成为山西省首家三级康复专科医院,自2024年4月起,经中国政府批准,武陟济民医院由二级甲等综合医院升级为三级综合医院,成为武陟县首家三级综合医院。
截至2024年12月31日,佰泽医疗的所有六家自有医院和黄山首康医院均成立了早癌筛查与防治中心、早癌筛查中心或早癌筛查与评估中心,将早癌筛查标准在基层应用和推广,以提供早癌筛查及肿瘤诊断和治疗的连续医疗服务。上述医院均已成立康复科及/或标准化及专业化的肿瘤康复中心,为肿瘤患者提供康复服务。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.